Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Regeneron Pharmaceuticals
Condition: Severe Hypertriglyceridemia (sHTG)
NCT03452228
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.